| Popis: |
Nizar Al-Ani,1 Faiq Gorial,1 Dina Yasiry,2 Fadya Al Derwibee,2 Yasameen Abbas Humadi,3 Nancy Sunna,4 Ali AlJabban5 1Rheumatology Unit, College of Medicine, University of Baghdad, Baghdad, Iraq; 2Department of Rheumatology, Baghdad Teaching Hospital, Baghdad, Iraq; 3College of Medicine, Al-Nahrain University, Baghdad, Iraq; 4Medical Department, Pfizer, Amman, Jordan; 5Medical Department, Pfizer, Baghdad, IraqCorrespondence: Ali AlJabbanPfizer, Building 5, Street 51, Sec. 611, AlDawoodi, Baghdad, IraqTel +964 7706056226Email AliAbdulmohsinAbdulkareem.AlJabban@pfizer.comPurpose: The development of evidence-based guidelines on early pharmacotherapeutic treatment of rheumatoid arthritis (RA) could be useful in Middle Eastern nations striving to improve outcomes in patients with this chronic, debilitating disease. Evidence obtained from local populations should inform such guidelines and therefore our aim was to use real-world data to evaluate the clinical responses of Iraqi patients with RA who received earlier or later treatment with the TNF inhibitor etanercept.Patients and Methods: Data from patients registered in the Iraq National Center of Rheumatology database from May 2012 to December 2018, inclusive, were analyzed retrospectively. Inclusion criteria were age ≥ 18 years, meeting the ACR/EULAR 2010 criteria for RA, referral for etanercept treatment, and ≥ 1 year of follow-up after etanercept initiation. Patients were excluded if they had received another biologic for RA. Included patients were categorized according to two separate stratifications: whether duration of RA symptoms prior to etanercept initiation was ≤ 10 or > 10 years (10 years represented the mean duration for the entire analysis population); and according to whether duration of RA symptoms prior to etanercept initiation was ≤ 1, > 1 to ≤ 4, > 4 to ≤ 10, > 10 to ≤ 20, or > 20 years. The evaluated outcomes were mean change from baseline in Clinical Disease Activity Index (CDAI) and 28-joint Disease Activity Score (DAS28) after 1 year of etanercept treatment.Results: A total of 979 patients were included. CDAI and DAS28 were significantly reduced (p< 0.001 for both) after 1 year of etanercept treatment irrespective of whether duration of RA symptoms prior to treatment was ≤ 10 or > 10 years. Patients with RA symptoms for ≤ 1 year prior to etanercept initiation showed a significant reduction in CDAI after 1 year of treatment (p=0.01).Conclusion: Iraqi patients with RA who received earlier treatment with etanercept had superior outcomes compared with those who received later treatment.Keywords: autoimmunity, biologics, delayed treatment of rheumatoid arthritis, early treatment of rheumatoid arthritis, real-world data, TNF inhibitors |
